CL2012000091A1 - Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares. - Google Patents

Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares.

Info

Publication number
CL2012000091A1
CL2012000091A1 CL2012000091A CL2012000091A CL2012000091A1 CL 2012000091 A1 CL2012000091 A1 CL 2012000091A1 CL 2012000091 A CL2012000091 A CL 2012000091A CL 2012000091 A CL2012000091 A CL 2012000091A CL 2012000091 A1 CL2012000091 A1 CL 2012000091A1
Authority
CL
Chile
Prior art keywords
improve
angtl3
chondrocytes
polypeptides
drug
Prior art date
Application number
CL2012000091A
Other languages
English (en)
Spanish (es)
Inventor
Johnson Kristen
Jennings Lori
G Schultz Peter
Original Assignee
Novartis Ag
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag
Publication of CL2012000091A1 publication Critical patent/CL2012000091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2012000091A 2009-07-14 2012-01-12 Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares. CL2012000091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
CL2012000091A1 true CL2012000091A1 (es) 2012-10-26

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000091A CL2012000091A1 (es) 2009-07-14 2012-01-12 Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares.

Country Status (30)

Country Link
US (4) US9139633B2 (cg-RX-API-DMAC7.html)
EP (1) EP2453921B1 (cg-RX-API-DMAC7.html)
JP (1) JP5602850B2 (cg-RX-API-DMAC7.html)
KR (3) KR101590834B1 (cg-RX-API-DMAC7.html)
CN (2) CN102625830B (cg-RX-API-DMAC7.html)
AU (1) AU2010273570B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012000914B8 (cg-RX-API-DMAC7.html)
CA (1) CA2767826C (cg-RX-API-DMAC7.html)
CL (1) CL2012000091A1 (cg-RX-API-DMAC7.html)
CO (1) CO6491059A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120024A (cg-RX-API-DMAC7.html)
CU (1) CU24042B1 (cg-RX-API-DMAC7.html)
EA (1) EA023073B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011604A (cg-RX-API-DMAC7.html)
ES (1) ES2541217T3 (cg-RX-API-DMAC7.html)
GT (1) GT201200011A (cg-RX-API-DMAC7.html)
IL (2) IL217383A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00572A (cg-RX-API-DMAC7.html)
MA (1) MA33423B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000707A (cg-RX-API-DMAC7.html)
MY (1) MY160951A (cg-RX-API-DMAC7.html)
NZ (1) NZ597306A (cg-RX-API-DMAC7.html)
PE (2) PE20160507A1 (cg-RX-API-DMAC7.html)
PL (1) PL2453921T3 (cg-RX-API-DMAC7.html)
PT (1) PT2453921E (cg-RX-API-DMAC7.html)
SG (1) SG177318A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000655A1 (cg-RX-API-DMAC7.html)
UA (1) UA104031C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011008773A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200078B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN110198447B (zh) 2011-11-08 2022-01-04 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CA2904160C (en) 2013-03-15 2022-08-23 The California Institute For Biomedical Research Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis
FI3143026T3 (fi) 2014-05-13 2024-10-10 Novartis Ag Yhdisteitä ja koostumuksia kondrogeneesin indusoimiseksi
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR20190084287A (ko) 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US12257243B2 (en) 2018-12-06 2025-03-25 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US7687460B2 (en) * 2000-10-16 2010-03-30 Genentech, Inc, Methods of treatment using wisp polypeptides
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
AU2003270454B2 (en) * 2002-09-09 2010-05-20 Nektar Therapeutics Water-soluble polymer alkanals
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5269411B2 (ja) * 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
IN2012DN00572A (cg-RX-API-DMAC7.html) 2015-06-12
US10064918B2 (en) 2018-09-04
WO2011008773A2 (en) 2011-01-20
GT201200011A (es) 2013-12-10
KR20180000337A (ko) 2018-01-02
MY160951A (en) 2017-03-31
CA2767826A1 (en) 2011-01-20
PL2453921T3 (pl) 2015-11-30
EP2453921A2 (en) 2012-05-23
EA023073B1 (ru) 2016-04-29
PE20160507A1 (es) 2016-05-20
EA201200118A1 (ru) 2012-09-28
KR101590834B1 (ko) 2016-02-12
TN2011000655A1 (en) 2013-05-24
AU2010273570A1 (en) 2012-02-02
BR112012000914A8 (pt) 2017-12-19
US11241482B2 (en) 2022-02-08
IL217383A0 (en) 2012-02-29
MX2012000707A (es) 2012-03-21
US20160213748A1 (en) 2016-07-28
CN102625830B (zh) 2016-03-02
CN105601728A (zh) 2016-05-25
US10555990B2 (en) 2020-02-11
US20190000922A1 (en) 2019-01-03
WO2011008773A3 (en) 2011-08-25
ZA201200078B (en) 2013-01-30
UA104031C2 (uk) 2013-12-25
JP5602850B2 (ja) 2014-10-08
CR20120024A (es) 2012-06-11
CU20120007A7 (es) 2013-02-26
MA33423B1 (fr) 2012-07-03
BR112012000914B1 (pt) 2021-04-06
AU2010273570B2 (en) 2014-07-03
PE20120570A1 (es) 2012-05-19
HK1164169A1 (en) 2012-09-21
CN102625830A (zh) 2012-08-01
CN105601728B (zh) 2020-01-10
NZ597306A (en) 2014-03-28
ES2541217T3 (es) 2015-07-16
EP2453921B1 (en) 2015-05-27
PT2453921E (pt) 2015-09-25
IL217383A (en) 2016-08-31
US9139633B2 (en) 2015-09-22
US20120177644A1 (en) 2012-07-12
US20200108122A1 (en) 2020-04-09
SG177318A1 (en) 2012-03-29
IL247310B (en) 2018-04-30
EP2453921A4 (en) 2012-12-19
CA2767826C (en) 2015-11-24
KR20120029472A (ko) 2012-03-26
ECSP12011604A (es) 2012-06-29
CO6491059A2 (es) 2012-07-31
KR20160015403A (ko) 2016-02-12
BR112012000914A2 (pt) 2017-08-08
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
BR112012000914B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CL2012000091A1 (es) Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares.
CL2008000121A1 (es) Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.
CL2011002768A1 (es) Polipéptido mutante fgf21; ácido nucleico que lo codifica; vector; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar un trastorno metabólico.
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
AR066848A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1)
CO6640331A2 (es) Tratamiento anti-envejecimiento de la piel
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
CL2012003655A1 (es) Uso de proteina alfa-n-acetilglucosaminidasa (naglu) recombinante para tratar sindrome de sanfilippo tipo b (san b); proteina de fusion terapeutica que comprende un dominio naglu y una porcion de objetivo lisosomal.
AR092076A1 (es) Proteinas homodimericas
TN2009000124A1 (en) Injectable depot composition and its process of preparation
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
CU24206B1 (es) Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
CL2014002406A1 (es) Metodo para el tratamiento de la depresion refractaria o resistente al taratamiento que comprende administrar esketamina por via intravenosa o intranasal sola o en combinacion con uno o mas antidepresivos; composicion farmaceutica; y su uso en el tratamiento de la depresion refractaria o resistente al tratamiento.
CL2012002706A1 (es) Composicion farmaceutica termogelificante estabilizada compuesta por anestesicos locales con un ph de al menos el pka de dichos anestesicos, que comprende a) la forma basica de uno o mas anestesicos de tipo amida, b) 10 a 30% de un aceite de ricino polioxietilado, y c) al menos 15% de uno o mas tensioactivos; y su metodo de preparacion.
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
CL2012003641A1 (es) Compuesto analogo de glucagon que comprende sustituciones de los residuos aminoacidos en las posiciones 3 y/o 4 del glucagón nativo y que tiene actividad en el receptor de glucagon y/o el receptor de glp-1; composicion farmaceutica que comprende el compuesto; uso del compuesto para prevenir aumento de peso o promover perdida de peso en un sujeto que lo necesita.
PE20150648A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
AR069135A1 (es) Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
AR103714A1 (es) Proteínas específicas para pioverdina y pioquelina
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
AR061929A1 (es) Acidos nucleicos de union al factor derivado de celulas estomales sdf-1